These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7983749)

  • 1. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    Groenink M; Moore JP; Broersen S; Schuitemaker H
    J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    O'Brien WA; Mao SH; Cao Y; Moore JP
    J Virol; 1994 Aug; 68(8):5264-9. PubMed ID: 8035523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD
    J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS
    J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    Dey B; Del Castillo CS; Berger EA
    J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization.
    Klasse PJ; McKeating JA
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):595-604. PubMed ID: 8369164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.
    Harrowe G; Cheng-Mayer C
    Virology; 1995 Jul; 210(2):490-4. PubMed ID: 7618285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.
    O'Brien WA; Chen IS; Ho DD; Daar ES
    J Virol; 1992 May; 66(5):3125-30. PubMed ID: 1373203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies.
    Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S
    Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
    Hwang SS; Boyle TJ; Lyerly HK; Cullen BR
    Science; 1992 Jul; 257(5069):535-7. PubMed ID: 1636088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.
    Moore JP; Burkly LC; Connor RI; Cao Y; Tizard R; Ho DD; Fisher RA
    AIDS Res Hum Retroviruses; 1993 Jun; 9(6):529-39. PubMed ID: 8347397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    Moore JP; McKeating JA; Norton WA; Sattentau QJ
    J Virol; 1991 Mar; 65(3):1133-40. PubMed ID: 1995942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.
    Lagenaur LA; Villarroel VA; Bundoc V; Dey B; Berger EA
    Retrovirology; 2010 Feb; 7():11. PubMed ID: 20158904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.
    Bouma P; Leavitt M; Zhang PF; Sidorov IA; Dimitrov DS; Quinnan GV
    J Virol; 2003 Jul; 77(14):8061-71. PubMed ID: 12829845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1.
    Mammano F; Salvatori F; Ometto L; Panozzo M; Chieco-Bianchi L; De Rossi A
    J Virol; 1995 Jan; 69(1):82-92. PubMed ID: 7527089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.
    Stamatatos L; Werner A; Cheng-Mayer C
    J Virol; 1994 Aug; 68(8):4973-9. PubMed ID: 8035496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.
    Kozak SL; Platt EJ; Madani N; Ferro FE; Peden K; Kabat D
    J Virol; 1997 Feb; 71(2):873-82. PubMed ID: 8995603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.